- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Act of 1934
Date of Report (Date of earliest event reported): AUGUST 13, 2002
PEREGRINE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-17085 95-3698422
(State or other (Commission (I.R.S. Employer
jurisdiction File Number) Identification No.)
of incorporation)
14272 FRANKLIN AVENUE, SUITE 100
TUSTIN, CALIFORNIA 92780-7017
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (714) 508-6000
- --------------------------------------------------------------------------------
ITEM 5. OTHER EVENTS.
On August 13, 2002, the Registrant issued a press release announcing
that it had sold to one institutional investor 2.9 million shares of its common
stock pursuant to its shelf registration statement for aggregate gross proceeds
$1,856,000.
In connection with the offering, the Company paid in cash placement
agent fees in the amount of $92,800. A copy of the press release is attached
hereto as Exhibit 99.1
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Exhibit Name of Exhibit
------- ---------------
99.1 Press release of Registrant dated August 13, 2002.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
PEREGRINE PHARMACEUTICALS, INC.
Date: August 13, 2002 By: /s/ Edward J. Legere,
-------------------------------------
Edward J. Legere,
President and Chief Executive Officer
2